GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (OTCPK:IGXT) » Definitions » Equity-to-Asset

Intelgenx Technologies (Intelgenx Technologies) Equity-to-Asset

: -1.48 (As of Dec. 2023)
View and export this data going back to 2006. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Intelgenx Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-12.25 Mil. Intelgenx Technologies's Total Assets for the quarter that ended in Dec. 2023 was $8.28 Mil. Therefore, Intelgenx Technologies's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -1.48.

The historical rank and industry rank for Intelgenx Technologies's Equity-to-Asset or its related term are showing as below:

IGXT' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.48   Med: 0.25   Max: 0.73
Current: -1.48

During the past 13 years, the highest Equity to Asset Ratio of Intelgenx Technologies was 0.73. The lowest was -1.48. And the median was 0.25.

IGXT's Equity-to-Asset is ranked worse than
93.17% of 1566 companies
in the Biotechnology industry
Industry Median: 0.67 vs IGXT: -1.48

Intelgenx Technologies Equity-to-Asset Historical Data

The historical data trend for Intelgenx Technologies's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 -0.09 0.22 -0.37 -1.48

Intelgenx Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.61 -1.17 -1.34 -1.48

Competitive Comparison

For the Biotechnology subindustry, Intelgenx Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelgenx Technologies Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Intelgenx Technologies's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Intelgenx Technologies's Equity-to-Asset falls into.



Intelgenx Technologies Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Intelgenx Technologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-12.247/8.282
=-1.48

Intelgenx Technologies's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-12.247/8.282
=-1.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intelgenx Technologies  (OTCPK:IGXT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Intelgenx Technologies Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelgenx Technologies (Intelgenx Technologies) Business Description

Traded in Other Exchanges
Address
6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and United States.
Executives
Atai Life Sciences Ag 10 percent owner KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v. 10 percent owner 524 BROADWAY, NEW YORK NY 10013
Karen Kalayajian officer: VP, Finance&Admin - Subsidiary 4896 RUE EDOUARD-BRUNETTE, LAVAL A8 H7T 0J4
Dwight Gorham officer: CEO 15B BARKLEY ST, ARNPRIOR A6 K7S 3G8
David Kideckel officer: SVP, Corp. Dev&SA - Subsidiary 23 PEVERIL HILL SOUTH, TORONTO, ON A6 M6C 3A7
Horst G Zerbe 10 percent owner, officer: Chief Executive Officer 714 MAIN ROAD, HUDSON A8 JOP1H0
Andre Godin officer: CFO 440 DES CARMANTINES, LAVAL A8 H7X 0B6
Tommy Kenny officer: VP IP,Lgl Affairs - Subsidiary 88 CH. DES SAULES, ST-ADOLPHE D' HOWARD A8 J0T 2B0
Dana Matzen officer: VP Business+Corp. Development 4771 RUE SHERBROOKE O., WESTMOUNT A8 H3Z1G5
Ingrid Zerbe 10 percent owner, officer: Corporate Secretary 714 MAIN ROAD, HUDSON A8 J0P1H0
Rodolphe Obeid officer: Vice President, Operations 4779 RUE VILLERET, PIERREFOND A8 H9K1P6
Bernard Boudreau director 2 TURNMILL DR., HALIFAX A5 B3M4H2
John Edward Durham officer: Vice President Manufacturing 102 MAYFAIR, HUDSON A8 J0P1H0
Mark Nawacki director 118 ARLINGTON AVENUE, WESTMOUNT A8 H3Y2W4
Robert J. Bechard officer: VP Corporate Development 141 EASTON AVENUE, MONTREAL WEST A8 H4X 1L4